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Abstract
Background: Aberrations in histone post-translational modifications (hPTMs) have been linked with various
pathologies, including cancer, and could not only represent useful biomarkers but also suggest possible targetable
epigenetic mechanisms. We have recently developed an approach, termed pathology tissue analysis of histones by
mass spectrometry (PAT-H-MS), that allows performing a comprehensive and quantitative analysis of histone PTMs
from formalin-fixed paraffin-embedded pathology samples. Despite its great potential, the application of this
technique is limited by tissue heterogeneity.
Methods: In this study, we further implemented the PAT-H-MS approach by coupling it with techniques aimed at
reducing sample heterogeneity and selecting specific portions or cell populations within the samples, such as
manual macrodissection and laser microdissection (LMD).
Results: When applied to the analysis of a small set of breast cancer samples, LMD-PAT-H-MS allowed detecting more
marked changes between luminal A-like and triple negative patients as compared with the classical approach. These
changes included not only the already known H3 K27me3 and K9me3 marks, but also H3 K36me1, which was found
increased in triple negative samples and validated on a larger cohort of patients, and could represent a potential novel
marker distinguishing breast cancer subtypes.
Conclusions: These results show the feasibility of applying techniques to reduce sample heterogeneity, including laser
microdissection, to the PAT-H-MS protocol, providing new tools in clinical epigenetics and opening new avenues for
the comprehensive analysis of histone post-translational modifications in selected cell populations.
Keywords: Histone post-translational modifications, PAT-H-MS, Laser microdissection, Proteomics, Epigenetic marker,
Formalin-fixed paraffin embedded, Mass spectrometry
Background
Histone post-translational modifications (hPTMs) gener-
ate a complex combinatorial code that is crucial to
regulate gene expression and determine cell fate [1].
Increasing evidence has linked aberrations in hPTMs
with various pathologies, including cancer, suggesting
that they could represent useful biomarkers for patient
stratification. Indeed, after the landmark discoveries of
the loss of H4-lysine 16 acetylation (H4K16ac) and H4-
lysine 20 trimethylation (H4K20me3) in cancer [2], and
of the prognostic value of hPTMs in various types of
cancers [3, 4], many more histone marks have been rec-
ognized as possible biomarkers in different diseases, and
particularly in cancer [5]. In addition, because changes
in hPTM levels are usually the result of the aberrant ex-
pression or mislocalization of histone modifying en-
zymes [6], profiling histone modification in disease
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could not only help uncover possible epigenetic mecha-
nisms underlying different pathologies but also provide
novel epigenetic pathways targetable for therapy. Indeed,
since epigenetic changes, unlike genetic ones, are intrin-
sically reversible and can be overturned, epigenetic ther-
apies are a promising avenue in translational research.
In recent years mass spectrometry (MS) has emerged as a
powerful method to analyze hPTMs, thanks to its accuracy,
its unbiased nature, and its ability to accurately quantify
modifications and their combinations [7], which represent
important advantages over traditional antibody based-
methods. However, the potential offered by the MS-based
analysis of hPTMs in clinical cancer samples has been left
largely unexploited. Indeed, most of the studies employing
MS-based techniques, which can provide a comprehensive
and quantitative view on hPTM patters, have focused on
cell lines and animal tissue, while clinical samples are
usually tested through antibody-based techniques.
Recently, we have reported for the first time a method
that allows the MS-based analysis of hPTMs from human
pathology tissues, termed pathology tissue analysis of
histones by mass spectrometry (PAT-H-MS) [8], which
combines protocols used for global proteomic studies of
formalin-fixed paraffin-embedded (FFPE) tissues [9] with
a proteomic workflow optimized for hPTM analysis [10].
By using this method, we revealed significant changes in
histone H3 methylation patterns between luminal A-like
and triple negative breast cancer subtypes. By combining
the power of the MS-based analysis of hPTMs with the
enormous amount of clinical information contained in
FFPE archives, which represent the storage method of
choice for clinical specimens, PAT-H-MS is a significant
technological advancement in clinical epigenetics.
However, a limitation of this approach, which is shared
by any other application in which FFPE sections are used
as starting material, is tissue heterogeneity. This is a par-
ticular issue for tumor specimens, which often contain
nontumoral cells that can mask or reduce the contribu-
tion of the tumor cells. In this study, we implemented
the PAT-H-MS approach by coupling it with techniques
aimed at reducing sample heterogeneity and selecting
specific portions or cell populations within the samples,
such as manual macrodissection and laser microdissec-
tion (LMD), and show the potential of LMD-PAT-H-MS
by applying it to a small panel of breast cancer luminal
A-like and triple negative samples.
Methods
Collection of specimens and preparation of FFPE tissues
Spleen tissue was collected from a leukemic mouse with
splenomegaly, washed in PBS and incubated for 16 h at
room temperature in a 4% paraformaldehyde solution.
The fixed spleen was then routinely dehydrated with
increasing concentrations of ethanol (70, 80, 90, and
100%) and subsequently included in paraffin using a
tissue processor (Leica ASP300).
Glioblastoma (GBM) specimens were collected from
patients at the Department of Neurosurgery at Istituto
Neurologico Carlo Besta. Human GBM-derived neuro-
spheres were obtained and grown as previously de-
scribed [11]. Prior to injection in mice, the neurospheres
were mechanically dissociated, and the cells were resus-
pended in 2 μL of phosphate-buffered saline and stereo-
taxically injected into the nucleus caudatus (1 mm
posterior, 3 mm left lateral, 3.5 mm in depth from
bregma) of 5-week-old female nu/nu CD1 mice (Charles
River, Wilmington, MA). Whole mouse brains were
collected and processed as described above.
Breast cancer frozen and FFPE specimens were ob-
tained from patients with duct invasive carcinoma at the
European Institute of Oncology, who were subjected to
mastectomy or breast conserving surgery. FFPE resec-
tion specimens of duct invasive breast carcinoma for
LMD were selected from the archive of the Institute of
Pathology Heidelberg with the support of the National
Center for Tumor Diseases (NCT, Heidelberg, Germany).
Tumor cellularity was evaluated histologically, and the as-
sessment of hormone and Her-2 receptors and the Ki-67
labeling index was performed as previously described [8].
Luminal A-like and triple negative subtypes were defined
as follows: luminal A-like: ER and/or PgR(+), HER2(−),
Ki67 < 20%; triple negative: ER, PgR, and HER2(−), irre-
spective of Ki67 score.
PAT-H-MS
Histones were isolated from FFPE tissues as recently de-
scribed [8]. Briefly, four 10-μm tissue sections were
deparaffinized with four washes in hystolemon (Dasit
Group Carlo Erba) and rehydrated from 100% ethanol to
water (through intermediate incubations in ethanol 95,
70, 50, and 20%). Tissue samples were resuspended in
200 μL of 20 mM Tris pH 7.4 containing 2% SDS and
were homogenized by sonication in a Branson Digital
Sonifier 250 with a 3-mm microtip. Proteins were then
extracted and de-crosslinked at 95 °C for 45 min and
65 °C for 4 h. The amount of histones was estimated by
sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE) gel following protein detection
with colloidal Comassie staining (Expedeon) by compari-
son with known amounts of recombinant histone H3.1
(New England Biolabs). For PAT-H-MS coupled with
manual macrodissection or laser microdissction, 10-μm
sections were placed on glass slides (Leica Microsys-
tems) and deparaffinized by incubation in xylene (Carlo
Erba, Milan, Italy) for 1 min. Tissue sections were subse-
quently rehydrated in decreasing concentrations of
ethanol (100, 95, and 75%) and rinsed in deionized water
for 30 s. The slides were stained with hematoxylin for
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2 min, washed in deionized water, and dehydrated by
incubation in 75% ethanol for 30 s. Each step was per-
formed at room temperature. When using manual
macrodissection, the tissue areas corresponding to the
tumor xenografts and the normal mouse brain were
morphologically evaluated by visualization under a
microscope. The two areas, which were clearly identifi-
able macroscopically, were scraped off the slide with a
scalpel into an eppendorf tube, washed once with 1 ml
of histolemon to remove any remaining paraffin and
rehydrated by a 3 min incubation at room temperature
in decreasing concentrations of ethanol (100, 70, 50, 20,
and water) followed by a 3 min centrifugation. The
tissue was then processed as in the original PAT-H-MS
protocol.
PAT-H-MS coupled with LMD
Cancer areas were collected in Eppendorf tubes from
tissue sections by laser microdissection, using a Leica
LMD 7000 instrument (Leica Microsystems, Wetzlar,
Germany) in the “draw and cut” mode with the follow-
ing laser settings: wavelength 349 nm, pulse energy 2 μJ,
numerical aperture 55, speed 15, specimen balance 35,
head current 100%, pulse frequency 5000 Hz, and focus
offset 65. Tissue pieces were transferred at the bottom
of the tubes through a 3-min centrifugation at maximum
speed. Tubes were opened carefully to avoid losing tissue
pieces and were processed as described above for macro-
dissected tissue.
Super-SILAC
A histone-focused super-stable isotope labeling by amino
acid in cell culture (SILAC) approach was used as we
have recently described [12]. MDA-MB-231, MDA-MB-
468, MDA-MB-453, and MDA-MB-361 breast cancer
cells lines were grown in SILAC-DMEM (Euroclone)
supplemented with 2 mM L-glutamine, 146 mg/l of
lysine (Sigma-Aldrich), 84 mg/l L-13C6
15N4-arginine (Arg-
10, Sigma-Aldrich), 10% dialyzed serum (Life Technolo-
gies), and penicillin/streptomycin for at least eight
doublings to obtain complete labeling with heavy-labeled
aminoacids. Histones were isolated from the different
cell lines through nuclei isolation on a sucrose cush-
ion followed by acidic extraction, as described [13],
mixed in equal amounts, lyophilized, and stored at
−80 °C until use.
Histone digestion
About 2–5 μg of histones per run per sample were sepa-
rated on a 17% SDS-PAGE gel and bands corresponding
to histone H3 were excised and in-gel digested as previ-
ously described [13]. Briefly, gel bands were cut in pieces
and de-stained with repeated washes in 50% acetonitrile
(ACN) in H2O, alternated with dehydration steps in
100% ACN. Gel pieces were then in-gel chemically alky-
lated with D6-acetic anhydride (Sigma-Aldrich) 1:9 in
1 M NH4HCO3, using CH3COONa as catalyzer. After
shaking for 3 h at 37 °C, chemically modified gel slices
were washed with NH4HCO3, alternated with ACN at
increasing percentages (from 50 to 100). The in-gel di-
gestion was performed overnight with 100 ng/μL trypsin
(Promega) in 50 mM NH4HCO3 at 37 °C, in order to
obtain an “Arg-C like” in-gel digestion that originates
histone peptides of optimal length for MS analysis by
cleaving at the C-terminal of arginine residues. Finally,
digested peptides were extracted using 5% formic acid
alternated with ACN 100%. In SILAC experimental set-
ups, unlabeled and heavy-labeled histones were mixed in
equal amounts prior to gel separation, and then processed
as described above. Digested peptides were desalted and
concentrated using a combination of reversed-phase C18/
C and strong cation exchange (SCX) chromatography on
handmade nanocolumns (StageTips). Digested peptides
were then eluted with 80% ACN/0.5% acetic acid and
5% NH4OH/30% methanol from C18/C and SCX
StageTips, respectively. Eluted peptides were lyophi-
lized, resuspended in 1% TFA, pooled, and subjected
to LC-MS/MS analysis.
LC-MS/MS
Peptide mixtures were separated by reversed-phase
chromatography on an in-house-made 25-cm column
(inner diameter 75 μm, outer diameter 350 μm, outer
diameter 1.9 μm ReproSil, Pur C18AQ medium), using
an ultra-nanoflow high-performance liquid chromatog-
raphy (HPLC) system (EASY-nLC™ 1000, Thermo Fisher
Scientic) or an EASY-Spray column (Thermo Fisher
Scientic), 50 cm (inner diameter 75 μm, PepMap C18,
2 μm particles), which were connected online to a Q
Exactive HF instrument (Thermo Fisher Scientific)
through a Nanospray Flex™ or an EASY-Spray™ Ion
Sources (Thermo Fisher Scientific), respectively. Solvent
A was 0.1% formic acid (FA) in ddH2O and solvent B
was 80% ACN plus 0.1% FA. Peptides were injected in
an aqueous 1% TFA solution at a flow rate of 500 nl/
min and were separated with a 100-min linear gradient
of 0–40% solvent B, followed by a 5-min gradient of 40–
60% and a 5-min gradient of 60–95% at a flow rate of
250 nl/min. The Q Exactive HF instrument was operated
in the data-dependent acquisition (DDA) mode to auto-
matically switch between full-scan MS and tandem mass
spectrometry (MS/MS) acquisition. Survey full-scan MS
spectra (m/z 300–1650) were analyzed in the Orbitrap
detector with resolution of 35,000 at m/z 400. The five
most intense peptide ions with charge states ≥2 were se-
quentially isolated to a target value for MS1 of 3 × 106
and fragmented by HCD with a normalized collision
energy setting of 25%. The maximum allowed ion
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accumulation times were 20 ms for full scans and 50 ms
for MS/MS, and the target value for MS/MS was set to
1 × 106. The dynamic exclusion time was set to 20 s, and
the standard mass spectrometric conditions for all
experiments were as follows: spray voltage of 2.4 kV, no
sheath, and auxiliary gas flow.
Data analysis
Acquired RAW data were analyzed by the integrated
MaxQuant software v.1.5.2.8, which performed peak list
generation and protein identification using the Androm-
eda search engine [14]. The Uniprot HUMAN_histones
1502 databases was used for peptide identification.
Enzyme specificity was set to Arg-C. The estimated false
discovery rate of all peptide identifications was set at a
maximum of 1%. The mass tolerance was set to 6 ppm for
precursor and fragment ions. No missed cleavages were
allowed, and the minimum peptide length was set to
six amino acids. Variable modifications included lysine
D3-acetylation (+45.0294 Da); lysine monomethylation
(+59.0454, corresponding to the sum of D3-acetylation
(+45.0294) and monomethylation (+14.016 Da)); dimethy-
lation (+28.031 Da); trimethylation (+42.046 Da); and ly-
sine acetylation (+42.010 Da). To reduce the search time
and the rate of false positives, which increase with increas-
ing the number of variable modifications included in the
database search [15], the raw data were analyzed through
multiple parallel MaxQuant jobs [16], setting different
combinations of variable modifications: (1) D3-acetylation,
lysine monomethylation with D3-acetylation, dimethyla-
tion, and lysine acetylation, (2) D3-acetylation, lysine
monomethylation with D3-acetylation, dimethylation, and
trimethylation, and (3) D3-acetylation, lysine monomethy-
lation with D3-acetylation, trimethylation, and lysine
acetylation. Peptides with Andromeda scores less than 60
and localization probability scores less than 0.75 were re-
moved. Identifications and retention times were used to
guide the manual quantification of each modified peptide
using QualBrowser version 2.0.7 (ThermoFisher Scien-
tific). Site assignment was evaluated using QualBrowser
and MaxQuant Viewer 1.3.0.5. Extracted ion chromato-
grams (XIC) were constructed for each doubly charged
precursor based on its m/z value, using a mass tolerance
of 10 ppm and a mass precision up to four decimals. For
each histone-modified peptide, the percent relative abun-
dance (%RA) was estimated by dividing the area under the
curve (AUC) of each modified peptide for the sum of the
areas corresponding to all the observed forms of that
peptide [17]. For SILAC experiments, Arg10 was selected
as heavy label (multiplicity = 2) in MaxQuant. The
heavy form of each modified peptide was quantified
from its XIC and the % RA calculated. L/H ratios of
relative abundances were used to compare samples. To
better visualize differences among samples, the ratio of
one sample relative to the standard was divided by the
average ratios across the samples, obtaining “normal-
ized” ratios, which were visualized and clustered using
Perseus [18], with correlation distance and complete
linkage as parameters. Differences between luminal A-
like and triple negative samples were assessed by t test
analysis using GraphPad Prism. For statistical analysis,
the ratio for peptides quantitated reliably in the spike-
in standard but not in the light channel (encircled grey
in Fig. 4a) was considered as 0, while those peptides
that could not be quantitated in the heavy channel
(grey in Fig. 4a), giving an infinite L/H ratio, were not
included in the analysis.
Results
Evaluation of PAT-H-MS compatibility with histological
staining
Tissue sections are usually required to be stained with
hematoxylin, alone or coupled with eosin, prior to laser
microdissection and other techniques to reduce sample
heterogeneity, to better visualize the areas of interest.
Therefore, we tested whether the staining procedure can
interfere with the PAT-H-MS protocol. To this aim, we
performed parallel histone isolations and hPTM analysis
from FFPE sections, either stained with hematoxylin and
eosin (H&E) with routine staining procedures or left un-
stained as a control, using mouse spleen as a source of
tissue (Fig. 1a). We processed the same starting amount
of material-four 10-μm-thick sections-and obtained ap-
proximately 80 μg of histone octamer from the classical
PAT-H-MS protocol and 40 μg from the H&E-stained
sections. Although the yield is lower starting from
stained sections, the SDS-PAGE run of the two samples
shows very similar protein patterns and purity (Fig. 1a,
bottom), and the amount obtained from H&E-stained
sections is anyhow largely sufficient for MS-based hPTM
analysis, which usually requires 4 μg of histones per run.
Importantly, the % relative abundance (%RA) profile for
the 25 differentially modified histone H3 peptides that
can be analyzed by PAT-H-MS is basically identical
using the two extraction methods (Fig. 1b, c), suggesting
that histological staining does not affect hPTM detection
and profiling.
PAT-H-MS coupled with manual tissue macrodissection
If the area of interest of a tissue section is well defined
and sufficiently extended, it can be manually dissected,
using a scalpel or razor blade, directly off the tissue sec-
tions. Such macrodissection is a relatively quick and in-
expensive procedure that can dramatically increase the
homogeneity of the tissue. We applied this approach in
combination with PAT-H-MS to analyze orthotopic glio-
blastoma patient-derived xenografts. Because the whole
mouse brain, which contains both the normal mouse
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tissue and the human tumor tissue, was fixed and em-
bedded in paraffin, analyzing the tumor hPTM patterns
without any enrichment would not be feasible, thus
making this an ideal case to test our method. Since glio-
blastoma is a very aggressive cancer, the tumor often
represents a significant portion of the sample (Fig. 2a),
which can be easily identified after H&E staining and
manually macrodissected. We analyzed three large xeno-
grafts originating from three glioblastoma patients
(Fig. 2a), obtaining octamer yields ranging between 50
and 60 μg from seven to ten 10-μm-thick sections
(Fig. 2b). As a control, we also macrodissected and in-
cluded in the analysis the mouse normal brain tissue
corresponding to each of the xenografts (Fig. 2a, b). To
quantitate more accurately the various histone marks,
and particularly the low abundance ones, we used the
histone-focused super-SILAC approach that we have re-
cently described, mixing the histone extracted from the
FFPE sections with a mix that is used as an internal
standard [8, 12]. This strategy originated the SILAC
“normalized” ratios (see “Experimental procedures”) dis-
played in Fig. 2c, which show in human tumor samples
a pattern that is clearly different from that found in nor-
mal mouse brain, as expected (Fig. 2c, Additional file 1:
Dataset S1).
We also sought to apply this strategy to a tumor of re-
duced size (Fig. 2d). According with the lower amount
of starting material, the yield of histone obtained was
also lower compared with the other samples (approxi-
mately 3 μg (Fig. 2b)). Nevertheless, we were able to
quantify all the peptides usually analyzed by PAT-H-MS
by using 2 μg of histones from this preparation for di-
gestion and LC-MS/MS analysis (Additional file 1: Data-
set S1). This amount of starting material, which roughly
corresponds to an area of 8 mm2 using ten 10-μm-thick
sections, is approaching the lower limit of detection for
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this approach. The number of sections should be
adjusted based on the size of the area of interests, for in-
stance 20 sections should be used for an area that is half
the size of the one used here. However, for small tumors
or other small features of interest the major limit is rep-
resented by the technical capability to manually dissect
small areas. Indeed, manual macrodissection is usually
adequate only when the area to be dissected is at least a
few millimeters in diameter.
Feasibility of coupling PAT-H-MS with laser
microdissection
An alternative to manual macrodissection that provides
improved precision is LMD, which allows producing
homogeneous tissue cell subpopulations under direct
microscopic visualization. LMD has been used in con-
junction with many different downstream applications,
including global proteomic analyses [19, 20] and the
genomic counterpart of our approach, pathology tissue-
chromatin immunoprecipitation (PAT-ChIP [21, 22]).
We recently employed the PAT-H-MS approach to
profile hPTM patterns in breast cancer patient samples,
revealing significant changes in histone H3 methylation
marks between the luminal A-like and triple negative
subtypes [8]. In particular, we observed higher levels of
K27me3-containing peptides in luminal A-like samples,
as already reported in IHC studies [23, 24], and higher
levels of K9me3-containing peptides in triple negative
samples. For this study, we employed samples having a
tumor cellular content of at least 50%, to ensure that a
good portion of the sample being analyzed was indeed
tumoral. Ideally, though, by selecting only the tumor
cells, the detection of more, and more marked, differences
is expected. In order to evaluate the feasibility of coupling
LMD with our PAT-H-MS approach, we processed three
samples belonging to the luminal A-like and triple nega-
tive subtypes using our classical approach (the sample
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had tumor cell content of at least 50%, excluding the
adipocytes) or PAT-H-MS coupled with LMD (Fig. 3a-c;
Additional file 2: Figure S1). As starting amount, we
used four 10-μm-thick sections for the classical ap-
proach, while we doubled the number of sections for the
LMD samples, to compensate for the reduction of mater-
ial due to the selection of the tumor cells. When the
amount of tumor cells in the slide was particularly low,
such as in the case of the LuA3 and TN3 samples, we fur-
ther increased the number of slides (Fig. 3c). Figure 3a, b
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Fig. 3 PAT-H-MS coupled with laser microdissection. a Schematic representation of the procedures used to isolate histones from FFPE mouse
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shows the Coomassie-stained SDS-PAGE and H&E-
stained sections for two representative samples. For all the
sample processes, we obtained histones in the amount
and purity sufficient for the subsequent LC-MS/MS ana-
lysis. Histone yields ranged between 14 and 70 μg (15–
50 μg for the classical protocol) and varied mostly based
on the amount of tissue present in the sections (Fig. 3b,
Additional file 2: Figure S1). To test the lower limit of our
approach, for sample TN1 we performed LMD-PAT-H-
MS using either one or seven sections. Remarkably, al-
though the amount of histones obtained from one section
was lower, as expected, we were able to analyze the
whole set of modifications quantifiable by PAT-H-MS
(Additional file 3: Dataset S2). As an example of the
quality of the results that we obtained from this sample,
Fig. 3d shows the extracted ion chromatograms used for
peptide quantitation for the 14 differentially modified
forms of peptide 27–40, which represents the most
complex and challenging H3-modified peptide to profile.
While the intensity of the peaks is relatively low, they are
very sharp and even low abundance and isobaric peptides
can be clearly distinguished and quantitated. The amount
of material that was microdissected from one section of
sample TN1 corresponds to approximately 450,000 cells,
which is the minimum amount of cells that we suggest to
use for this type of experiment.
PAT-H-MS coupled with LMD reveals histone marks
distinguishing luminal A-like and triple negative breast
cancer patient samples
Once demonstrated the technical feasibility of perform-
ing PAT-H-MS on LMD samples, we compared the
hPTM patterns of the small set of luminal A-like and
triple negative samples that we have analyzed, using both
the LMD-coupled and classical approaches (Fig. 4).
Non-supervised clustering separates luminal A-like and
triple negative samples; although, using LMD, TN2
seems to be different from the other two triple negative
samples and more similar to luminal A-like samples
(Fig. 4a). Some technical variability, demonstrated by the
incorrect clustering of some of the technical replicates
for the luminal A-like samples, could be observed, but
was mostly at the level of low abundance modifications
(e.g. K9me3/K14ac) and involved mild differences, that
do not impinge on the separation of the two subtypes.
Confirming our previous findings [8], we identified sev-
eral modified peptides that are significantly different in
the two groups, including the K27me3- and K9me3-
containing peptides. Remarkably, while in the LMD
samples we detected significant differences in K9me3,
K9me3/K14ac, K27me3, and K27me3/K36me1 peptides,
in the samples processed with the classical protocol the
difference for the K9me3 and K27me3/K36me1 peptides
was not significant (Fig. 4a, b). This is very likely due to
the “dilution” effect due to the presence of normal cells
within the specimen and is in accordance with the ob-
servation that K9me3 levels are higher in tumor cells
compared with the surrounding normal cells in triple
negative samples, but not in luminal A-like samples
(Fig. 4c). A decrease of the K27me2/K36me1 peptide,
which we had already observed [8], could also be
detected in triple negative samples only with the LMD
approach. Interestingly, while the peptide carrying
K36me1 in combination with K27me2 decreases, likely
due to the contribution of the K27me2 mark, which is
also reduced, the K36me1 peptide increases in triple
negative samples and could represent an additional bio-
marker distinguishing luminal A-like and triple negative
samples. This novel finding was validated on a larger co-
hort of 10 luminal A-like and 10 triple negative patients,
where the peptide H3 27–40 was profiled by using clas-
sical PAT-H-MS approach (Additional file 3: Dataset S2).
While corroborating previously found differences, this
larger screening also confirmed the increase of the
K36me1 mark in triple negative samples (Fig. 5a, b). Few
novel significant changes were found in samples proc-
essed through the classical approach, but not through
LMD-PAT-H-MS, such as an increase in the K36me2
mark. These could reflect changes happening in the
normal/non tumoral cells surrounding the tumor,
which were excluded by the analysis with LMD, or be
randomly detected in this small set of samples due to
the heterogeneity of the sections taken as whole. Never-
theless, taken together, these results confirm our hy-
pothesis that by selecting only the tumor cells by LMD,
we can detect more marked changes among samples,
even in a small dataset such as the one analyzed here
and possibly avoid identifying changes due to other
tissue components.
Discussion
In this study, we show the feasibility of applying tech-
niques to reduce sample heterogeneity, including laser
microdissection, to the MS-based analysis of hPTM
achieved through the PAT-H-MS protocol that we have
recently developed [8]. This approach may be useful to
separate macroscopic parts of tissues, as exemplified by
the isolation of xenografts from mouse brain tissue, or
to more finely select specific cell populations, such as
tumor cells in a tumor specimen. We compared the
classical PAT-H-MS approach with the LDM-coupled
strategy, and we showed that while both methods allow
distinguishing differences in a small panel of breast
tumor samples belonging to different subtypes, LMD-
PAT-H-MS allows detecting more marked changes,
which results in more significant differences.
However, one issue related to microdissected tissue to
consider is the amount of starting material. Whereas for
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the classical PAT-H-MS approach we found that four 10-
μm-thick sections are sufficient for all the >100 samples
that we processed so far, laser microdissected samples
may require more starting sections, depending on the size
of the area of interest to be dissected. For sections con-
taining a large portion of cancerous tissue, such as TN1,
one section, corresponding to approximately 450,000 cells,
is enough, but when dissecting smaller areas the number
of sections should be increased and may become the lim-
ing factor of the approach.
Another aspect to consider is the sample size and the
labor associated with LMD. Histones can be obtained
from FFPE sections using the classical PAT-H-MS ap-
proach in approximately 6 h, without the need for any
specialized equipment. In the case of the LMD proto-
col, the dissection time, which is approximately 2 h per
section containing 450,000 tumor cells, should be
added to the PAT-H-MS processing time. In addition,
an LMD instrument and trained personnel are needed.
Therefore, when deciding which approach to use, the
benefits and costs of applying such procedures to the
analysis of hPTMs should be weighted, taking into
account the number of samples, the starting amount
available, and the availability of LMD instrumentation.
We believe that LDM-PAT-H-MS should represent the
approach of choice when dealing with a small sample
size for which enough starting material is available, to
maximize the differences and the specificity of the re-
sults. On the contrary, when processing a large number
of samples, the classical PAT-H-MS may be preferred,
provided that the samples are chosen to keep tissue
heterogeneity to a minimum. For instance, tumor
cellularity within a tumor specimen should be 50% or
higher. However, in some cases, for instance, when a
specific cell subpopulation or a specific morphological
feature is needed, LDM-PAT-H-MS is the only alter-
native available.
Importantly, the analysis of a small cohort of breast
cancer confirmed global higher levels of K9me3, and
lower levels of K27me3, in triple negative breast cancer
samples compared with luminal A-like samples, corrob-
orating our previous results [8] and suggesting possible
novel epigenetic biomarkers that may help distinguish-
ing triple negative samples from other breast cancer
subtypes. Among these, we have validated on a larger co-
hort of patients the increase of K36me1, which was not
previously reported. Further investigation on this differ-
ence, as well as those involving the K27me3 and K9me3
marks, will uncover possible novel epigenetic mechanisms
underlying breast cancer.
Conclusions
Taken together, the results presented in this study show
the feasibility of applying techniques to reduce sample
heterogeneity, including laser microdissection, to the
PAT-H-MS protocol, providing new tools in clinical epi-
genetics and opening new avenues for the comprehen-
sive analysis of hPTMs in selected cell populations.
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Fig. 2. (XLSX 33 kb)
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Additional file 2: Figure S1. H&E staining of representative sections for
the six breast cancer samples analyzed by LMD-PAT-H-MS and classical
PAT-H-MS. Scale bar = 10 mm. (PDF 1881 kb)
Additional file 3: Dataset S2. Dataset containing the measured AUCs
and L/H ratios for the breast cancer samples shown in Figs. 3, 4, and 5
and Additional file 2: Figure S1. (XLSX 105 kb)
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